(NASDAQ: ARGX) Argenx Se's forecast annual revenue growth rate of 1,391.12% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Argenx Se's revenue in 2025 is $1,917,647.On average, 10 Wall Street analysts forecast ARGX's revenue for 2025 to be $245,544,500,835, with the lowest ARGX revenue forecast at $230,069,645,123, and the highest ARGX revenue forecast at $260,408,526,253. On average, 10 Wall Street analysts forecast ARGX's revenue for 2026 to be $323,779,910,950, with the lowest ARGX revenue forecast at $306,906,822,705, and the highest ARGX revenue forecast at $366,614,141,153.
In 2027, ARGX is forecast to generate $384,939,294,099 in revenue, with the lowest revenue forecast at $351,276,246,191 and the highest revenue forecast at $400,471,033,687.